Genotyping News and Research

RSS

Scientists identify key molecular switches that control age-related memory impairment

Even among the healthiest individuals, memory and cognitive abilities decline with age. This aspect of normal aging can affect an individual's quality of life and capability to live independently but the rate of decline is variable across individuals.

7 May 2014

Armetheon reaches agreement with FDA on SPA for final pivotal trial of tecarfarin

Armetheon, Inc., today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the final pivotal trial of tecarfarin.

29 Apr 2014

Illumina launches VeriSeq PGS for preimplantation genetic screening of embryos

Illumina, Inc. today announced the launch of VeriSeq PGS, a next-generation sequencing solution developed for preimplantation genetic screening of embryos using Illumina's NextSeq 500 and MiSeq® sequencing systems.

From Illumina, Inc. 29 Apr 2014

New study sheds light on mysterious gene that influences cardiovascular health

A new study from researchers at the University of Ottawa Heart Institute (UOHI), published today in Cell Reports, sheds light on a mysterious gene that likely influences cardiovascular health.

26 Apr 2014

Roche's cobas HPV Test gets FDA approval for first-line primary screening for cervical cancer

Roche announced today that the U.S. Food and Drug Administration approved the cobas HPV (Human Papillomavirus) Test for use as a first-line primary screening test for cervical cancer in women 25 and older. The approval follows the March 12 unanimous recommendation from the Microbiology Devices Panel of the FDA's Medical Devices Advisory Committee, making the cobas HPV Test the first and only HPV test in the United States approved for first-line primary screening.

From Roche Sequencing and Life Science 25 Apr 2014

ARCA biopharma announces genetic screening of first patient in GENETIC-AF Phase 2B/3 clinical trial

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 adaptive design clinical trial.

From Medtronic 18 Apr 2014

Scientists design new system for molecular blood group typing

Scientists in France have designed a new system for molecular blood group typing that offers blood banks the possibility of extensive screening of blood donors at a relatively low cost. Their approach is described in the current issue of The Journal of Molecular Diagnostics.

10 Apr 2014

Variations in woman's genome may contribute to her risk of developing ovarian cancer

Variations in a woman's genome may contribute to her risk of developing ovarian cancer. Researchers using data collected by the Ovarian Cancer Association Consortium have discovered uncommon variants in new regions of the genome that influence ovarian cancer risk, and will present their findings on April 6, 2014 at the American Association for Cancer Research Annual Meeting in San Diego, CA.

7 Apr 2014

ABL enters into licensing agreement with CRP-Santé for COMET software

Advanced Biological Laboratories (ABL) S.A., a Luxembourg-based company today announced that it has entered into an exclusive worldwide licensing agreement with CRP-Santé, a Luxembourg-based public research center active in the field of clinically oriented biomedical research, for its COMET (COntext-based Modeling for Expeditious Typing) software, a tool designed to rapidly analyze and optimally subtype large genetic data sets arising from epidemiological or antiretroviral resistance in the human immunodeficiency virus (HIV) and hepatitis C virus (HCV) fields.

2 Apr 2014

Researchers identify two new genes associated with intellectual disability

Researchers at the Centre for Addiction and Mental Health have discovered two new genes linked to intellectual disability, according to two research studies published concurrently this month in the journals Human Genetics and Human Molecular Genetics.

1 Apr 2014

Genetic testing could help determine drug dosage, reduce side effects

Usually pharmaceutical companies determine the drug dosage just as a mean value. This amount may be too much for patients who absorb the substance faster, and too little for those with a slower metabolism.

27 Mar 2014

A fast, non-invasive method to genotype late-onset Alzheimer's disease

The apolipoprotein E gene ε4 allele is considered a negative factor for neural regeneration in late-onset Alzheimer's disease cases.

27 Mar 2014

Cell-free DNA analysis allows noninvasive tumour genotype monitoring

Noninvasive tumour genotyping using cell-free plasma DNA analysis is feasible, say US researchers who believe the technique will aid patient diagnosis and monitoring.

24 Mar 2014

Higher genetic risk of obesity may amplify effects of fried food consumption on body weight

People with a genetic predisposition to obesity are at a higher risk of obesity and related chronic diseases from eating fried foods than those with a lower genetic risk, according to a new study from researchers from Harvard School of Public Health, Brigham and Women's Hospital, and Harvard Medical School.

19 Mar 2014

Scientists discover gene variation that makes humans have healthier blood lipid levels, reduced risk of heart attacks

Scientists have discovered a previously unrecognized gene variation that makes humans have healthier blood lipid levels and reduced risk of heart attacks -- a finding that opens the door to using this knowledge in testing or treatment of high cholesterol and other lipid disorders.

17 Mar 2014

WuXi Genome Center buys Illumina HiSeq X Ten sequencing system

Illumina, Inc. and WuXi PharmaTech (Cayman) Inc., a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company with operations in China and the United States, today announced that the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing system.

From Illumina, Inc. 10 Mar 2014

Treating cystic fibrosis: an interview with Simon Bedson, Senior Vice President and International General Manager at Vertex

Cystic fibrosis is a rare, life-shortening genetic disease for which there is no cure. It affects more than 75,000 people worldwide. In CF, thick, sticky mucus blocks the passages in many organs, leading to a variety of symptoms. In particular, mucus builds up and clogs airways in the lungs making it easier for bacteria to grow.

5 Mar 2014

FDA approves KALYDECO for people with cystic fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.

26 Feb 2014

Driver mutations found in more than half of adenosquamous lung carcinomas

Analysis of a large cohort of Chinese patients with adenosquamous lung carcinoma has identified known mutant kinases in more than half of the tumours, researchers report in the Journal of Thoracic Oncology.

19 Feb 2014

Fluidigm acquires DVS Sciences

Fluidigm Corp. today announced it has completed its acquisition of DVS Sciences, Inc. With the closing of the acquisition, Fluidigm adds a high-parameter single-cell protein analysis platform to its industry-leading single-cell genomics platforms to create a comprehensive portfolio of advanced technologies serving the rapidly growing single-cell genomics and proteomics markets.

13 Feb 2014